JP2021525270A - Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 - Google Patents
Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 Download PDFInfo
- Publication number
- JP2021525270A JP2021525270A JP2020565928A JP2020565928A JP2021525270A JP 2021525270 A JP2021525270 A JP 2021525270A JP 2020565928 A JP2020565928 A JP 2020565928A JP 2020565928 A JP2020565928 A JP 2020565928A JP 2021525270 A JP2021525270 A JP 2021525270A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- mixture
- alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 title claims abstract description 57
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 title claims abstract description 57
- 239000003112 inhibitor Substances 0.000 title abstract description 6
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title abstract description 3
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 195
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 148
- 201000011510 cancer Diseases 0.000 claims abstract description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 11
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 10
- 208000013403 hyperactivity Diseases 0.000 claims abstract description 9
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims abstract description 7
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims abstract description 7
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 267
- 238000000034 method Methods 0.000 claims description 121
- -1 halogen halogen Chemical class 0.000 claims description 79
- 210000004027 cell Anatomy 0.000 claims description 72
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 45
- 239000000843 powder Substances 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 37
- 208000035475 disorder Diseases 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 18
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 201000000053 blastoma Diseases 0.000 claims description 13
- 201000008184 embryoma Diseases 0.000 claims description 13
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 201000009030 Carcinoma Diseases 0.000 claims description 12
- 125000006001 difluoroethyl group Chemical group 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 10
- 206010039491 Sarcoma Diseases 0.000 claims description 10
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 208000009956 adenocarcinoma Diseases 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 210000002308 embryonic cell Anatomy 0.000 claims description 9
- 230000002496 gastric effect Effects 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 208000007569 Giant Cell Tumors Diseases 0.000 claims description 8
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 7
- 206010029260 Neuroblastoma Diseases 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 7
- 201000008873 bone osteosarcoma Diseases 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 6
- 235000011613 Pinus brutia Nutrition 0.000 claims description 6
- 241000018646 Pinus brutia Species 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 230000036244 malformation Effects 0.000 claims description 6
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 6
- 210000000115 thoracic cavity Anatomy 0.000 claims description 6
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 6
- 210000001635 urinary tract Anatomy 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 5
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
- 206010057249 Phagocytosis Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 5
- 206010057644 Testis cancer Diseases 0.000 claims description 5
- 210000000941 bile Anatomy 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000008298 histiocytosis Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000000564 macroglobulinemia Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 208000025113 myeloid leukemia Diseases 0.000 claims description 5
- 230000008782 phagocytosis Effects 0.000 claims description 5
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 201000003120 testicular cancer Diseases 0.000 claims description 5
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 5
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 4
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 208000003076 Osteolysis Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010033799 Paralysis Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 201000005969 Uveal melanoma Diseases 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 4
- 201000005962 mycosis fungoides Diseases 0.000 claims description 4
- 201000002575 ocular melanoma Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 210000004500 stellate cell Anatomy 0.000 claims description 4
- 210000002536 stromal cell Anatomy 0.000 claims description 4
- 210000002435 tendon Anatomy 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 208000037965 uterine sarcoma Diseases 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 3
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 3
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010062038 Lip neoplasm Diseases 0.000 claims description 3
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims description 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 201000008183 Pulmonary blastoma Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 206010043515 Throat cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 210000004252 chorionic villi Anatomy 0.000 claims description 3
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 201000010235 heart cancer Diseases 0.000 claims description 3
- 208000024348 heart neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 3
- 210000004153 islets of langerhan Anatomy 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 201000006721 lip cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 3
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 3
- 210000004379 membrane Anatomy 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 208000037830 nasal cancer Diseases 0.000 claims description 3
- 201000008026 nephroblastoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 208000021284 ovarian germ cell tumor Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000003154 papilloma Diseases 0.000 claims description 3
- 208000029211 papillomatosis Diseases 0.000 claims description 3
- 208000010916 pituitary tumor Diseases 0.000 claims description 3
- 208000010626 plasma cell neoplasm Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 3
- 230000001953 sensory effect Effects 0.000 claims description 3
- 208000037968 sinus cancer Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003445 Ascites Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000010392 Bone Fractures Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 206010050389 Cerebral ataxia Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010506 Congenital hydrocephalus Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000009129 Ear Neoplasms Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000026097 Factitious disease Diseases 0.000 claims description 2
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims description 2
- 206010017076 Fracture Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 208000003926 Myelitis Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000005228 Pericardial Effusion Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 206010052276 Pseudodementia Diseases 0.000 claims description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 2
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 208000018839 Wilson disease Diseases 0.000 claims description 2
- 238000005299 abrasion Methods 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 201000002454 adrenal cortex cancer Diseases 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 210000003567 ascitic fluid Anatomy 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 2
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 208000021245 head disease Diseases 0.000 claims description 2
- 208000003906 hydrocephalus Diseases 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004130 lipolysis Effects 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 210000004912 pericardial fluid Anatomy 0.000 claims description 2
- 210000004910 pleural fluid Anatomy 0.000 claims description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 201000008261 skin carcinoma Diseases 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000029584 urinary system neoplasm Diseases 0.000 claims description 2
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 241000248040 Globulosis Species 0.000 claims 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 1
- 208000004987 Macrophage activation syndrome Diseases 0.000 claims 1
- 206010064470 Muscle swelling Diseases 0.000 claims 1
- 102000006386 Myelin Proteins Human genes 0.000 claims 1
- 108010083674 Myelin Proteins Proteins 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 210000005012 myelin Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 6
- 206010062016 Immunosuppression Diseases 0.000 abstract description 3
- 206010027476 Metastases Diseases 0.000 abstract description 3
- 206010070308 Refractory cancer Diseases 0.000 abstract description 3
- 230000004770 neurodegeneration Effects 0.000 abstract description 3
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 337
- 235000019439 ethyl acetate Nutrition 0.000 description 156
- 239000000243 solution Substances 0.000 description 153
- 230000015572 biosynthetic process Effects 0.000 description 125
- 238000003786 synthesis reaction Methods 0.000 description 124
- 238000006243 chemical reaction Methods 0.000 description 109
- 230000002829 reductive effect Effects 0.000 description 104
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 95
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 93
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- 239000011734 sodium Substances 0.000 description 77
- 239000011541 reaction mixture Substances 0.000 description 57
- 238000004809 thin layer chromatography Methods 0.000 description 56
- 239000004698 Polyethylene Substances 0.000 description 55
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 52
- 239000007787 solid Substances 0.000 description 51
- 239000012267 brine Substances 0.000 description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
- 239000012044 organic layer Substances 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 239000003921 oil Substances 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 37
- 239000000725 suspension Substances 0.000 description 36
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 34
- 239000012043 crude product Substances 0.000 description 26
- 230000005764 inhibitory process Effects 0.000 description 26
- 239000000047 product Substances 0.000 description 24
- 239000008346 aqueous phase Substances 0.000 description 23
- 239000003208 petroleum Substances 0.000 description 23
- 108091000080 Phosphotransferase Proteins 0.000 description 22
- 239000000284 extract Substances 0.000 description 22
- 102000020233 phosphotransferase Human genes 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000004480 active ingredient Substances 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 21
- 239000007858 starting material Substances 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 17
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 17
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 17
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 17
- 229910004298 SiO 2 Inorganic materials 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 238000000159 protein binding assay Methods 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 238000012746 preparative thin layer chromatography Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 108091011896 CSF1 Proteins 0.000 description 8
- 101150022345 GAS6 gene Proteins 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 229940045348 brown mixture Drugs 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 229940125851 compound 27 Drugs 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 4
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 238000003026 viability measurement method Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 2
- RTMMSCJWQYWMNK-UHFFFAOYSA-N 2,2,2-trifluoroethyl trifluoromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(F)(F)F RTMMSCJWQYWMNK-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 239000004234 Yellow 2G Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- GTZCVFVGUGFEME-UHFFFAOYSA-N aconitic acid Chemical compound OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 229940127084 other anti-cancer agent Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 101150080066 proS1 gene Proteins 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- XUCYJGMIICONES-UHFFFAOYSA-N 1-fluoro-2-methyl-4-nitrobenzene Chemical compound CC1=CC([N+]([O-])=O)=CC=C1F XUCYJGMIICONES-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QJNRQJGEIYYPRW-UHFFFAOYSA-N 2,3-dimethoxyquinoline Chemical class C1=CC=C2N=C(OC)C(OC)=CC2=C1 QJNRQJGEIYYPRW-UHFFFAOYSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- CSSGKHVRDGATJL-UHFFFAOYSA-N 3-fluoro-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(F)=C1 CSSGKHVRDGATJL-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- MEWIPRPYWOTKFX-UHFFFAOYSA-N 4,4,4-trifluorobutanoyl chloride Chemical compound FC(F)(F)CCC(Cl)=O MEWIPRPYWOTKFX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UCTNTYHJFWMUBD-UHFFFAOYSA-N 4-chloro-3-oxobutanoic acid Chemical compound OC(=O)CC(=O)CCl UCTNTYHJFWMUBD-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010066817 Activation syndrome Diseases 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 description 1
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 238000003749 KINOMEscan Methods 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 238000012897 Levenberg–Marquardt algorithm Methods 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101150045565 Socs1 gene Proteins 0.000 description 1
- 101150043341 Socs3 gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000058018 Suppressor of Cytokine Signaling 1 Human genes 0.000 description 1
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 description 1
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 230000006043 T cell recruitment Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091077436 Tam family Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101150098329 Tyro3 gene Proteins 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940091179 aconitate Drugs 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000012635 anticancer drug combination Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000005817 fluorobutyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 108700024553 fms Genes Proteins 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000029712 muscle cell homeostasis Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- CPQCSJYYDADLCZ-UHFFFAOYSA-N n-methylhydroxylamine Chemical compound CNO CPQCSJYYDADLCZ-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- LFLZOWIFJOBEPN-UHFFFAOYSA-N nitrate, nitrate Chemical compound O[N+]([O-])=O.O[N+]([O-])=O LFLZOWIFJOBEPN-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- CXLGNJCMPWUZKM-UHFFFAOYSA-N oxane-4-carbaldehyde Chemical compound O=CC1CCOCC1 CXLGNJCMPWUZKM-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000023974 pharynx neoplasm Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- HJSRRUNWOFLQRG-UHFFFAOYSA-N propanedioic acid Chemical compound OC(=O)CC(O)=O.OC(=O)CC(O)=O HJSRRUNWOFLQRG-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000014680 small intestine neoplasm Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical class C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006407 thiazinanyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
Abstract
Description
Axl/Mer受容体チロシンキナーゼ(Axl/Mer RTK)はTAM(チロシン、Axl、Mer)受容体チロシンキナーゼの一員である。Axl/Mer RTKは2つのイムノグロブリン様ドメイン、これに続く2つのフィブロネクチン3型様ドメインからなる細胞外ドメインを特徴とする。Axl/Merの活性化は、その同族タンパク質リガンド、成長停止特異的6(Gas6)およびタンパク質S(Pros1)によりそれぞれ生じる。
本発明の目的は、特にがんなどの細胞増殖性疾患、さらには炎症性疾患および/または神経変性疾患も処置するための薬学的活性のある薬剤として使用することができる化合物および/またはその薬学的に許容される塩、ならびにこれらの化合物および/またはその薬学的に許容される塩のうちの少なくとも1種を薬学的活性成分として含む組成物を提供することである。
X1は、存在する各々において独立して、CR3およびNから選択され、
X2は、存在する各々において独立して、CR4およびNから選択され、
nは、存在する各々において独立して、0、1および2から選択され、
Aは、存在する各々において、以下のW基;
R1は、存在する各々において、水素;C1〜C6アルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキル;−(C=O)R5からなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R2は、存在する各々において、C1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキル;−NR7R8;−OR8からなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R3およびR4は、存在する各々において、水素;ハロゲン、例えば、ClまたはF;C1〜C3アルキル;OR5;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R5およびR6は、存在する各々において、水素;C1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R7は、存在する各々において、水素;C1〜C6アルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R8は、存在する各々において、水素;−CH(CH3)2;−C(CH3)3;C3〜C10シクロアルキル;C3〜C10ヘテロシクロアルキル;C1〜C4ハロアルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;ならびにC3〜C10シクロアルキル、C3〜C10ヘテロシクロアルキルおよびC1〜C4ハロアルキルのうちの1つまたは2つで置換されているC1〜C6アルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
Z1は、存在する各々において、水素;C1〜C6アルキル;(=O)、CN、OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;C3〜C10シクロアルキル;ハロゲン、OR7およびNR9R10のうちの1つまたはいくつかで置換されているC3〜C10シクロアルキル;C3〜C10ヘテロシクロアルキル;ハロゲン、C1〜C6アルキル、C3〜C10シクロアルキルおよびC1〜C4ハロアルキルのうちの1つまたはいくつかで置換されているC3〜C10ヘテロシクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、
R9およびR10は、存在する各々において、水素;C1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R11およびR12は、存在する各々において、C1〜C6アルキル;C3〜C10シクロアルキル;C3〜C10ヘテロシクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されている)
を有する化合物およびその薬学的に許容される塩に関する。
R1、R2、R3、R4、Z1、X1、X2およびnは上で定義された通りである)およびその薬学的に許容される塩を有し、
好ましくは、
R3およびR4が、存在する各々において、水素;ハロゲン、例えば、ClまたはF;必要に応じて置換されているC1〜C3アルキルからなる群から独立して選択され、
R8が、存在する各々において、水素;−CH(CH3)2;−C(CH3)3;C3〜C10シクロアルキル;C1〜C4ハロアルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;またはC3〜C10シクロアルキルおよびC1〜C4ハロアルキルのうちの1つまたは2つで置換されているC1〜C6アルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
Z1が、存在する各々において、水素;C1〜C6アルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;C3〜C10シクロアルキル;ハロゲン、OR7およびNR9R10のうちの1つまたはいくつかで置換されているC3〜C10シクロアルキル;C3〜C10ヘテロシクロアルキル;ハロゲン、C1〜C6アルキル、C3〜C10シクロアルキルおよびC1〜C4ハロアルキルのうちの1つまたはいくつかで置換されているC3〜C10ヘテロシクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択される化合物、およびその薬学的に許容される塩である。
R1、R2、R3、R4、Z1およびnは上で定義された通りであり、
ここで、好ましくは、
R3およびR4が水素である)
およびその薬学的に許容される塩を有する。
R2はOR8であり、R8は、−CH(CH3)2;−C(CH3)3;C1〜C4ハロアルキル;C3〜C10シクロアルキル、C3〜C10ヘテロシクロアルキルおよびC1〜C4ハロアルキルのうちの1もしくは2つで置換されているC1〜C6アルキル;またはC1〜C4ハロアルキル、特にトリフルオロメチル、ジフルオロメチル、フルオロメチル、トリフルオロエチル、ジフルオロエチル、フルオロエチル、トリフルオロプロピル、ジフルオロプロピル、フルオロプロピル、トリフルオロイソプロピル、ジフルオロイソプロピル、およびフルオロイソプロピルのうちの1つで置換されているC1〜C6アルキル
ならびにその薬学的に許容される塩から選択される。
R2はOR8であり、R8は、C1〜C4ハロアルキル、特にトリフルオロメチル、ジフルオロメチル、フルオロメチル、トリフルオロエチル、ジフルオロエチル、フルオロエチル、トリフルオロプロピル、ジフルオロプロピル、フルオロプロピル、トリフルオロイソプロピル、ジフルオロイソプロピル、およびフルオロイソプロピルのうちの1つ;またはC1〜C4ハロアルキル、特にトリフルオロメチル、ジフルオロメチル、フルオロメチル、トリフルオロエチル、ジフルオロエチル、フルオロエチル、トリフルオロプロピル、ジフルオロプロピル、フルオロプロピル、トリフルオロイソプロピル、ジフルオロイソプロピル、およびフルオロイソプロピルのうちの1つで置換されているC1〜C6アルキルから選択される。
医薬組成物
薬学的に許容される塩
投与および製剤
表
ここで以下の図および表について言及する。
(実施例1)
AxlおよびMerに対するキナーゼ結合アッセイ
結合アッセイ原理
AXLおよびMerに対する結合アッセイプロトコール
表1は、AXLおよびMerキナーゼ結合アッセイに対して得た結果を要約したものである。
(実施例2)
CSF1Rに対するキナーゼ結合アッセイ
結合アッセイ原理
CSF1Rに対する結合アッセイプロトコール
結合%阻害を以下のように計算した:
細胞Axl阻害アッセイ
Axl細胞アッセイ原理
H1299細胞を使用した酵素結合免疫吸着検定法(ELISA)
(実施例4)
細胞CSF1R阻害アッセイ
CSF1R細胞アッセイ原理
THP−1細胞を使用する酵素結合免疫吸着検定法(ELISA)
M−NFS−60細胞を使用するCell Titer−Glo(CTG)アッセイ
(実施例5)
BaF3−生存率アッセイにより測定される細胞のAxl、MerおよびCSF1R阻害
BaF3細胞に基づくアッセイ原理
BaF3細胞に基づくアッセイプロトコール
(実施例6)
結合活性(AxlおよびMer)および細胞活性の点からの、本発明の選択された化合物と、WO2016/166250の選択された化合物との比較。
(実施例7)
EMT−6およびMV4−11マウスモデル
a)EMT−6マウスモデル
同系モデル
EMT−6同系腫瘍モデル処置プロトコール
b)MV4−11マウスモデル
異種移植片モデル
MV4−11異種移植片腫瘍モデル処置プロトコール
(実施例8)
ジメトキシキノリンの一般的骨格の誘導体化
スキーム1−一般的合成経路I
スキーム2−化合物4に対する一般的合成
A4の合成に対する一般的手順
A5の合成に対する一般的手順
A6の合成に対する一般的手順
A7の合成に対する一般的手順
A8の合成に対する一般的手順
4の合成に対する一般的手順
スキーム3−化合物1に対する一般的合成
A10の合成に対する一般的手順
A11の合成に対する一般的手順
A12の合成に対する一般的手順
1の合成に対する一般的手順
スキーム4−化合物3に対する一般的合成
第1バッチ:
第2バッチ:
A14の合成に対する一般的手順
第1バッチ:
第2バッチ:
A15の合成に対する一般的手順
A16の合成に対する一般的手順
3の合成に対する一般的手順
スキーム5−化合物6に対する一般的合成
A18の合成に対する一般的手順
A19の合成に対する一般的手順
A20の合成に対する一般的手順
6の合成に対する一般的手順
スキーム6−化合物15に対する一般的合成
A22の合成に対する一般的手順
A23の合成に対する一般的手順
A24の合成に対する一般的手順
A25の合成に対する一般的手順
15の合成に対する一般的手順
スキーム7−化合物17および19に対する一般的合成
A27の合成に対する一般的手順
19の合成に対する一般的手順
17の合成に対する一般的手順
スキーム8−化合物63に対する一般的合成
A29の合成に対する一般的手順
A30の合成に対する一般的手順
63の合成に対する一般的手順
スキーム9−化合物23に対する一般的合成
A33の合成に対する一般的手順
A34の合成に対する一般的手順
A35の合成に対する一般的手順
A36の合成に対する一般的手順
23の合成に対する一般的手順
スキーム10−化合物34に対する一般的合成
A38の合成に対する一般的手順
A39の合成に対する一般的手順
A40の合成に対する一般的手順
A41の合成に対する一般的手順
A42の合成に対する一般的手順
A43の合成に対する一般的手順
34の合成に対する一般的手順
スキーム11−化合物35に対する一般的合成
B4の合成に対する一般的手順
B5の合成に対する一般的手順
B6の合成に対する一般的手順
B7の合成に対する一般的手順
B8の合成に対する一般的手順
B1−2の合成に対する一般的手順
A44の合成に対する一般的手順
A45の合成に対する一般的手順
35の合成に対する一般的手順
スキーム12−化合物44に対する一般的合成
A47の合成に対する一般的手順
44の合成に対する一般的手順
スキーム13−化合物120に対する一般的合成
D1−9の合成に対する一般的手順
A48の合成に対する一般的手順
A49の合成に対する一般的手順
120の合成に対する一般的手順
スキーム14−化合物115に対する一般的合成
B1−4の合成に対する一般的手順
115の合成に対する一般的手順
スキーム15−化合物53に対する一般的合成
A51の合成に対する一般的手順
B12の合成に対する一般的手順
B1−5の合成に対する一般的手順
53の合成に対する一般的手順
スキーム16−化合物58に対する一般的合成
B1−6の合成に対する一般的手順
58の合成に対する一般的手順
スキーム17−化合物176に対する一般的合成
A54の合成に対する一般的手順
A55の合成に対する一般的手順
A56の合成に対する一般的手順
A57の合成に対する一般的手順
A58の合成に対する一般的手順
A59の合成に対する一般的手順
A60の合成に対する一般的手順
A61の合成に対する一般的手順
A62の合成に対する一般的手順
176の合成に対する一般的手順
スキーム18−化合物178に対する一般的合成
A65の合成に対する一般的手順
A66の合成に対する一般的手順
178の合成に対する一般的手順
スキーム19−化合物179に対する一般的合成
A69の合成に対する一般的手順
A70の合成に対する一般的手順
C3の合成に対する一般的手順
179の合成に対する一般的手順
スキーム20−一般的合成経路II
A72の合成に対する一般的手順
C4の合成に対する一般的手順
16の合成に対する一般的手順
C2の合成に対する一般的手順
スキーム21−化合物29に対する一般的合成
参考文献
Claims (22)
- 一般式I:
X1は、存在する各々において独立して、CR3およびNから選択され、
X2は、存在する各々において独立して、CR4およびNから選択され、
nは、存在する各々において独立して、0、1および2から選択され、
Aは、存在する各々において、以下のW基;
R1は、存在する各々において、水素;C1〜C6アルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキル;−(C=O)R5からなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R2は、存在する各々において、C1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキル;−NR7R8;−OR8からなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R3およびR4は、存在する各々において、水素;ハロゲン、例えば、ClまたはF;C1〜C3アルキル;OR5;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R5およびR6は、存在する各々において、水素;C1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R7は、存在する各々において、水素;C1〜C6アルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R8は、存在する各々において、水素;−CH(CH3)2;−C(CH3)3;C3〜C10シクロアルキル;C3〜C10ヘテロシクロアルキル;C1〜C4ハロアルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;ならびにC3〜C10シクロアルキル、C3〜C10ヘテロシクロアルキルおよびC1〜C4ハロアルキルのうちの1つまたは2つで置換されているC1〜C6アルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
Z1は、存在する各々において、水素;C1〜C6アルキル;(=O)、CN、OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;C3〜C10シクロアルキル;ハロゲン、OR7およびNR9R10のうちの1つまたはいくつかで置換されているC3〜C10シクロアルキル;C3〜C10ヘテロシクロアルキル;ハロゲン、C1〜C6アルキル、C3〜C10シクロアルキルおよびC1〜C4ハロアルキルのうちの1つまたはいくつかで置換されているC3〜C10ヘテロシクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、
R9およびR10は、存在する各々において、水素;C1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R11およびR12は、存在する各々において、C1〜C6アルキル;C3〜C10シクロアルキル;C3〜C10ヘテロシクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されている、
化合物およびその薬学的に許容される塩。 - 一般式III:
R1、R2、R3、R4、Z1、X1、X2およびnは請求項1で定義された通りであり、
好ましくは、
R3およびR4が、存在する各々において、水素;ハロゲン、例えば、ClまたはF;必要に応じて置換されているC1〜C3アルキルからなる群から独立して選択され、
R8は、存在する各々において、水素;−CH(CH3)2;−C(CH3)3;C3〜C10シクロアルキル;C1〜C4ハロアルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;またはC3〜C10シクロアルキルおよびC1〜C4ハロアルキルのうちの1つまたは2つで置換されているC1〜C6アルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
Z1が、存在する各々において、水素;C1〜C6アルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキル;C3〜C10シクロアルキル;ハロゲン、OR7およびNR9R10のうちの1つまたはいくつかで置換されているC3〜C10シクロアルキル;C3〜C10ヘテロシクロアルキル;ハロゲン、C1〜C6アルキル、C3〜C10シクロアルキルおよびC1〜C4ハロアルキルのうちの1つまたはいくつかで置換されているC3〜C10ヘテロシクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択される、化合物およびその薬学的に許容される塩。 - n=0または1であり、Z1が、C1〜C6アルキル、特にメチル、エチル、プロピルまたはイソプロピル;C3〜C10シクロアルキル、特にC3シクロアルキル;C3〜C10ヘテロシクロアルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキルから選択される、請求項1から5のいずれかに記載の化合物、およびその薬学的に許容される塩。
- R2がOR8であり、R8が−CH(CH3)2;−C(CH3)3;C1〜C4ハロアルキル;C3〜C10シクロアルキル、C3〜C10ヘテロシクロアルキルおよびC1〜C4ハロアルキルのうちの1もしくは2つで置換されているC1〜C6アルキル;またはC1〜C4ハロアルキル、特にトリフルオロメチル、ジフルオロメチル、フルオロメチル、トリフルオロエチル、ジフルオロエチル、フルオロエチル、トリフルオロプロピル、ジフルオロプロピル、フルオロプロピル、トリフルオロイソプロピル、ジフルオロイソプロピル、およびフルオロイソプロピルのうちの1つで置換されているC1〜C6アルキルから選択される、請求項1から6のいずれかに記載の化合物、およびその薬学的に許容される塩。
- n=0または1であり、Z1が、C1〜C6アルキル、特にメチル、エチル、プロピルまたはイソプロピル;C3〜C10シクロアルキル、特にC3シクロアルキル;C3〜C10ヘテロシクロアルキル;OR5およびNR5R6のうちの1つまたは2つで置換されているC1〜C6アルキルから選択され、R5およびR6が、存在する各々において、水素;C1〜C6アルキル;C3〜C10シクロアルキル;C1〜C4ハロアルキルからなる群から独立して選択され、これらのいずれもが必要に応じて置換されており、
R2がOR8であり、R8が、−CH(CH3)2;−C(CH3)3;C1〜C4ハロアルキル;C3〜C10シクロアルキル、C3〜C10ヘテロシクロアルキルおよびC1〜C4ハロアルキルのうちの1つまたは2つで置換されているC1〜C6アルキル;またはC1〜C4ハロアルキル、特にトリフルオロメチル、ジフルオロメチル、フルオロメチル、トリフルオロエチル、ジフルオロエチル、フルオロエチル、トリフルオロプロピル、ジフルオロプロピル、フルオロプロピル、トリフルオロイソプロピル、ジフルオロイソプロピル、およびフルオロイソプロピルのうちの1つで置換されているC1〜C6アルキルから選択される、
請求項6および7のいずれかに記載の化合物、ならびにその薬学的に許容される塩。 - R2がOR8であり、R8が、C1〜C4ハロアルキル、特にトリフルオロメチル、ジフルオロメチル、フルオロメチル、トリフルオロエチル、ジフルオロエチル、フルオロエチル、トリフルオロプロピル、ジフルオロプロピル、フルオロプロピル、トリフルオロイソプロピル、ジフルオロイソプロピル、およびフルオロイソプロピルのうちの1つ;またはC1〜C4ハロアルキル、特にトリフルオロメチル、ジフルオロメチル、フルオロメチル、トリフルオロエチル、ジフルオロエチル、フルオロエチル、トリフルオロプロピル、ジフルオロプロピル、フルオロプロピル、トリフルオロイソプロピル、ジフルオロイソプロピル、およびフルオロイソプロピルのうちの1つで置換されているC1〜C6アルキルから選択される、先行する請求項のいずれかに記載の化合物。
- n=0または1であり、Z1が、メチル;エチル;プロピル;イソプロピル;C3シクロアルキル;C4シクロアルキル;およびC5シクロアルキルから選択される、先行する請求項のいずれかに記載の化合物。
- n=0または1であり、Z1が、メチル;エチル;プロピル;イソプロピル;C3シクロアルキル;C4シクロアルキル;およびC5シクロアルキルから選択され、
R2がOR8であり、R8が、C1〜C4ハロアルキル、特にトリフルオロメチル、ジフルオロメチル、フルオロメチル、トリフルオロエチル、ジフルオロエチル、フルオロエチル、トリフルオロプロピル、ジフルオロプロピル、フルオロプロピル、トリフルオロイソプロピル、ジフルオロイソプロピル、およびフルオロイソプロピルのうちの1つ;またはC1〜C4ハロアルキル、特にトリフルオロメチル、ジフルオロメチル、フルオロメチル、トリフルオロエチル、ジフルオロエチル、フルオロエチル、トリフルオロプロピル、ジフルオロプロピル、フルオロプロピル、トリフルオロイソプロピル、ジフルオロイソプロピル、およびフルオロイソプロピルのうちの1つで置換されているC1〜C6アルキルから選択される、請求項9および10のいずれかに記載の化合物。 - 請求項1から12のいずれかに記載の少なくとも1つの化合物を、少なくとも1種の薬学的に許容される担体、賦形剤および/または希釈剤と一緒に含む、組成物。
- 少なくとも1種の他の薬学的活性のある薬剤をさらに含む、請求項13に記載の組成物。
- 薬学的活性のある薬剤としての使用のための、好ましくは障害を処置する方法における使用のための、請求項1から12のいずれかに記載の化合物または請求項13から14のいずれかに記載の組成物。
- Axl/MerおよびCSF1R受容体チロシンキナーゼに関連する、伴う、引き起こされるまたは誘発される障害、特にAxl/MerおよびCSF1R(コロニー刺激因子1受容体)に関連する、伴う、または引き起こされる、好ましくは前記Axl/Merの機能亢進および前記CSF1Rの機能亢進に関連する、伴う、または引き起こされる障害の処置における使用のための、請求項1から12のいずれかに記載の化合物または請求項13から14のいずれかに記載の組成物。
- 前記障害が過剰増殖性障害、炎症性障害および神経変性障害から選択される、請求項15から16のいずれかに記載の使用のための化合物または組成物。
- 前記過剰増殖性障害ががんであり、好ましくは、腺癌、聴神経腫瘍、急性リンパ芽球性白血病、急性骨髄性白血病、副腎皮質癌、AIDS関連がん、AIDS関連リンパ腫、肛門がん、虫垂がん、星状細胞腫、非定型奇形腫様/ラブドイド腫瘍、膨大部癌、基底細胞癌、胆管がん、膀胱がん、骨がん、骨肉腫および悪性線維性組織球腫、脳幹神経膠腫、脳腫瘍、中枢神経系非定型奇形腫様/ラブドイド腫瘍、頭蓋咽頭腫、上衣芽腫、上衣細胞腫、髄芽腫、髄上皮腫、中間型松果体実質腫瘍、テント上原始神経外胚葉性腫瘍および松果体芽腫、脳および脊髄腫瘍、乳がん、尿膜管腫瘍、バーキットリンパ腫、カルチノイド腫瘍、脈絡膜の黒色腫、消化器がん、中枢神経系リンパ腫、子宮頸がん、子宮体がん、脊索腫、慢性リンパ球性白血病、慢性骨髄性白血病、慢性骨髄増殖性障害、結腸がん、直腸結腸がん、皮膚T細胞リンパ腫、類腱腫、菌状息肉腫、子宮内膜がん、食道がん、感覚神経芽腫、ユーイング肉腫ファミリー腫瘍、頭蓋外胚細胞腫瘍、性腺外胚細胞腫瘍、肝外胆管がん、耳腫瘍、眼内黒色腫、網膜芽腫、胆嚢がん、胃がん、消化管カルチノイド腫瘍、消化管間質腫瘍、消化管間質細胞腫瘍、婦人科の腫瘍、卵巣胚細胞腫瘍、妊娠性絨毛腫瘍、神経膠腫、胆嚢癌、有毛細胞白血病、頭頸部がん、心臓がん、肝細胞がん、組織球症、下咽頭がん、血液系新生物、島細胞腫瘍(内分泌性膵臓)、腎細胞がん、腎臓がん、ランゲルハンス細胞組織球症、喉頭がん、白血病、唇および口腔がん、肝臓がん、肺がん、非小細胞肺がん、小腸の腫瘍、小細胞肺がん、ホジキンリンパ腫、非ホジキンリンパ腫、原発性中枢神経系リンパ腫、マクログロブリン血症、骨の悪性線維性組織球腫および骨肉腫、黒色腫、メルケル細胞癌、中皮腫、原発不明の転移性頸部扁平上皮がん、スピナリオムス、多発性内分泌腺腫瘍症候群、骨髄異形成症候群、骨髄異形成/骨髄増殖性新生物、骨髄性白血病、多発性骨髄腫、骨髄増殖性障害、鼻腔および副鼻腔がん、鼻咽頭がん、神経芽細胞腫、口腔がん、中咽頭がん、骨肉腫および骨の悪性線維性組織球腫、卵巣がん、卵巣上皮がん、卵巣低悪性度腫瘍、乏突起膠腫、形質細胞腫、膵臓がん、乳頭腫症、副甲状腺がん、陰茎がん、咽頭がん、下垂体腫瘍、形質細胞新生物/多発性骨髄腫、胸膜肺芽腫、前立腺がん、直腸がん、腎細胞がん、移行性細胞がん、呼吸器がん、横紋筋肉腫、唾液腺がん、肉腫、皮膚精巣がん、ユーイング肉腫、カポジ肉腫、子宮肉腫、非黒色腫皮膚がん、黒色腫皮膚がん、皮膚癌、小腸がん、軟部組織肉腫、扁平上皮癌、扁平頸部がん、胃がん、軟組織腫瘍、精巣がん、咽喉がん、胸腺腫および胸腺癌、甲状腺がん、腎孟および尿管の移行性細胞がん、栄養膜腫瘍、睾丸がー妊娠性がん、泌尿器腫瘍、尿管および腎盂がん、尿道がん、尿路上皮癌、子宮がん、膣がん、外陰がん、ワルデンシュトレームマクログロブリン血症およびウィルムス腫瘍、身体の潜在空隙に滲出を引き起こす腫瘍、胸水、心嚢液貯留、腹膜滲出、別名腹水、巨細胞腫(GCT)、骨のGCT、色素性絨毛結節性滑膜炎(PVNS)、腱滑膜巨細胞腫(TGCT)、腱鞘のTGCT(TGCT−TS)から選択されるがんである、請求項17に記載の使用のための化合物または組成物。
- 前記炎症性障害が、骨関節炎、炎症性腸症候群、移植片拒絶反応、全身性エリテマトーデス、潰瘍性大腸炎、クローン病、慢性閉塞性肺疾患、肺気腫、川崎病、血球貪食症候群(マクロファージ活性化症候群)、多中心性細網組織球症、アテローム性動脈硬化症、一次性進行型多発性硬化症、tenpsy I型糖尿病、II型糖尿病、インスリン抵抗性、高血糖、肥満、脂肪分解、過好酸球増加症、骨粗鬆症、骨折の危険性の増加、パジェット病、高カルシウム血症、感染症媒介性骨溶解(例えば骨髄炎)、人工関節周囲のまたは磨耗粉媒介性骨溶解、子宮内膜症、炎症性疼痛、慢性疼痛、および骨痛から選択される、請求項17に記載の使用のための化合物または組成物。
- 前記神経変性障害が、Binswanger型認知症、前脳胞症、小頭症、脳性麻痺、先天性水頭症、腹水、進行性核上性麻痺、緑内障、ウィルソン病、アルツハイマー病および他の認知症、パーキンソン病(PD)およびPD関連障害、多発梗塞性認知症、前頭側頭認知症、仮性認知症、プリオン病、運動ニューロン疾患、ハンチントン病、脊髄小脳失調症、ならびに脊髄性筋萎縮症から選択される、請求項17に記載の使用のための化合物または組成物。
- 前記使用が、別の薬学的活性のある薬物または療法、特に放射線療法、化学療法剤、標的薬物および免疫チェックポイント阻害剤薬物と組み合わされる、請求項15から20のいずれかに記載の使用のための化合物または組成物。
- 過剰増殖性障害、炎症性障害および/または神経変性障害から選択される疾患の処置の方法であって、請求項1から12のいずれかに記載の化合物、または請求項13から14のいずれかに記載の組成物を、それを必要とする患者に投与することを含む、方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023174642A JP2023168629A (ja) | 2018-05-30 | 2023-10-06 | Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862677902P | 2018-05-30 | 2018-05-30 | |
US62/677,902 | 2018-05-30 | ||
PCT/EP2019/064214 WO2019229251A1 (en) | 2018-05-30 | 2019-05-31 | Quinoline derivatives as inhibitors of axl/mer rtk and csf1r |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023174642A Division JP2023168629A (ja) | 2018-05-30 | 2023-10-06 | Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021525270A true JP2021525270A (ja) | 2021-09-24 |
JP2021525270A5 JP2021525270A5 (ja) | 2021-12-09 |
JP7390313B2 JP7390313B2 (ja) | 2023-12-01 |
Family
ID=66770463
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020565928A Active JP7390313B2 (ja) | 2018-05-30 | 2019-05-31 | Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 |
JP2023174642A Pending JP2023168629A (ja) | 2018-05-30 | 2023-10-06 | Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023174642A Pending JP2023168629A (ja) | 2018-05-30 | 2023-10-06 | Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210163448A1 (ja) |
EP (1) | EP3774776A1 (ja) |
JP (2) | JP7390313B2 (ja) |
KR (1) | KR20210020882A (ja) |
CN (1) | CN112313216A (ja) |
AU (1) | AU2019276359A1 (ja) |
BR (1) | BR112020021370A2 (ja) |
CA (1) | CA3097694A1 (ja) |
IL (1) | IL278960B1 (ja) |
MX (1) | MX2020011636A (ja) |
PH (1) | PH12020551806A1 (ja) |
SG (1) | SG11202009971QA (ja) |
WO (1) | WO2019229251A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023186294A1 (en) * | 2022-03-30 | 2023-10-05 | Qurient Co., Ltd. | New forms of n-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-1-propyl-4-(2,2,2-trifluoroethoxy)-1h-pyrazole-3-carboxamide hydrochloride |
CN117637185B (zh) * | 2024-01-25 | 2024-04-23 | 首都医科大学宣武医院 | 一种基于影像的颅咽管瘤治疗辅助决策方法、系统及设备 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997017329A1 (fr) * | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant |
WO2011045084A1 (en) * | 2009-10-16 | 2011-04-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
JP2013536813A (ja) * | 2010-08-28 | 2013-09-26 | リード ディスカバリー センター ゲーエムベーハー | Axl阻害剤としての薬学的に活性な化合物 |
JP2014506925A (ja) * | 2011-02-28 | 2014-03-20 | カリトル サイエンシズ, エルエルシー | 置換型キノリン化合物及び使用方法 |
WO2016104617A1 (ja) * | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | キノリン誘導体 |
JP2018511624A (ja) * | 2015-04-14 | 2018-04-26 | キュリエント カンパニー, リミテッド | Tam rtkインヒビターとしてのキノリン誘導体 |
-
2019
- 2019-05-31 CA CA3097694A patent/CA3097694A1/en active Pending
- 2019-05-31 JP JP2020565928A patent/JP7390313B2/ja active Active
- 2019-05-31 SG SG11202009971QA patent/SG11202009971QA/en unknown
- 2019-05-31 EP EP19728645.3A patent/EP3774776A1/en active Pending
- 2019-05-31 KR KR1020207034321A patent/KR20210020882A/ko unknown
- 2019-05-31 CN CN201980036560.3A patent/CN112313216A/zh active Pending
- 2019-05-31 US US17/047,961 patent/US20210163448A1/en active Pending
- 2019-05-31 WO PCT/EP2019/064214 patent/WO2019229251A1/en active Application Filing
- 2019-05-31 MX MX2020011636A patent/MX2020011636A/es unknown
- 2019-05-31 BR BR112020021370-5A patent/BR112020021370A2/pt unknown
- 2019-05-31 IL IL278960A patent/IL278960B1/en unknown
- 2019-05-31 AU AU2019276359A patent/AU2019276359A1/en active Pending
-
2020
- 2020-10-29 PH PH12020551806A patent/PH12020551806A1/en unknown
-
2023
- 2023-10-06 JP JP2023174642A patent/JP2023168629A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997017329A1 (fr) * | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant |
WO2011045084A1 (en) * | 2009-10-16 | 2011-04-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
JP2013536813A (ja) * | 2010-08-28 | 2013-09-26 | リード ディスカバリー センター ゲーエムベーハー | Axl阻害剤としての薬学的に活性な化合物 |
JP2014506925A (ja) * | 2011-02-28 | 2014-03-20 | カリトル サイエンシズ, エルエルシー | 置換型キノリン化合物及び使用方法 |
WO2016104617A1 (ja) * | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | キノリン誘導体 |
JP2018511624A (ja) * | 2015-04-14 | 2018-04-26 | キュリエント カンパニー, リミテッド | Tam rtkインヒビターとしてのキノリン誘導体 |
Non-Patent Citations (2)
Title |
---|
"RN:2028271-26-1", DATABASE REGISTRY [ONLINE], RETRIEVED FROM STN, JPN6022044644, 9 November 2016 (2016-11-09), ISSN: 0005080545 * |
JOURNAL OF MEDICINAL CHEMISTRY, vol. Vol.59(8), JPN6022044645, 10 November 2015 (2015-11-10), pages 3593 - 3608, ISSN: 0004902759 * |
Also Published As
Publication number | Publication date |
---|---|
IL278960B1 (en) | 2024-04-01 |
SG11202009971QA (en) | 2020-11-27 |
JP7390313B2 (ja) | 2023-12-01 |
EP3774776A1 (en) | 2021-02-17 |
US20210163448A1 (en) | 2021-06-03 |
CA3097694A1 (en) | 2019-12-05 |
WO2019229251A1 (en) | 2019-12-05 |
KR20210020882A (ko) | 2021-02-24 |
JP2023168629A (ja) | 2023-11-24 |
CN112313216A (zh) | 2021-02-02 |
BR112020021370A2 (pt) | 2021-01-19 |
MX2020011636A (es) | 2020-12-07 |
AU2019276359A1 (en) | 2020-10-29 |
PH12020551806A1 (en) | 2021-05-17 |
IL278960A (en) | 2021-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7372255B2 (ja) | 免疫調節剤としての複素環式化合物 | |
CN108699001B (zh) | 作为免疫调节剂的杂环化合物 | |
CN109563071B (zh) | 作为atf4途径抑制剂的化学化合物 | |
CN107667101B (zh) | 作为tam rtk抑制剂的喹啉衍生物 | |
KR101086967B1 (ko) | 과다증식성 질환의 치료를 위한 erbb 유형 i 수용체티로신 키나제 억제제로서의 n4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물 | |
JP2020504742A (ja) | 新規のベンジルアミノ置換キナゾリンおよびsos1阻害剤としての誘導体 | |
JP2019081786A (ja) | Trkaキナーゼ阻害剤としてのn−ピロリジニル、n’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物 | |
TW201838996A (zh) | 喹唑啉化合物 | |
CN113637007A (zh) | Rho激酶抑制剂 | |
JP2019510043A (ja) | Tam阻害剤としてのピロロトリアジン化合物 | |
PH12015500938B1 (en) | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | |
AU2014364744A1 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
WO2020025030A1 (zh) | 一类具有免疫调节功能的芳香化合物的制备和应用 | |
TW201900632A (zh) | N-(氮雜芳基)環內醯胺-1-甲醯胺衍生物及其製備方法和應用 | |
KR20220024191A (ko) | 항암제 조합 요법 | |
JP2023168629A (ja) | Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 | |
US20230339891A1 (en) | Uracil derivatives as mer-axl inhibitors | |
WO2014157687A1 (ja) | アセトアミド基を有する1,2,4-トリアジン-6-カルボキサミド誘導体 | |
WO2019043372A1 (en) | SUBSTITUTES OF SULFONYLAZACYCLES USED AS MODULATORS OF THE HEDGEHOG SIGNALING PATHWAY (HH) | |
WO2017211216A1 (zh) | 稠合嘧啶哌啶环衍生物及其制备方法和应用 | |
RU2812631C2 (ru) | Производные хинолина в качестве ингибиторов рецепторной тирозинкиназы axl/mer и csf1r | |
WO2022253327A1 (zh) | 一类具有免疫调节功能的化合物的制备和应用 | |
WO2023116865A1 (zh) | 含吡唑类衍生物、其药学上可接受的盐及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211101 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211101 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221017 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221024 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230316 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231006 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231017 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7390313 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |